Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05112315

Clinical Impact of the IBox As an Early Intervention TooL

Clinical Impact of the IBox As an Early Intervention TooL: a Prospective Randomised Controlled Trial to Assess the Use of a Software Predicting Allograft Survival in the Follow-up of Kidney Transplanted Patients.

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
507 (actual)
Sponsor
Predict4Health · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by showing that the use of Predigraft could improve patient's follow-up.

Detailed description

The study aims to demonstrate improvement of the prevalence of biopsies leading to therapeutic change in the Predigraft group compared to the Standard of care group in kidney transplanted patients. It is hypothesized that using Predigraft as a monitoring tool will help the physician detect earlier and more often abnormalities with the patient allograft. This should lead to an increased number of biopsies leading to therapeutic change. These biopsies should be performed earlier than without the iBox monitoring tool. This would improve long-term allograft function, kidney allograft and patient survival.

Conditions

Interventions

TypeNameDescription
DEVICEPredigraftThe Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.

Timeline

Start date
2022-02-18
Primary completion
2025-02-01
Completion
2025-02-01
First posted
2021-11-08
Last updated
2024-10-04

Locations

16 sites across 6 countries: Austria, France, Germany, Israel, Spain, United Kingdom

Source: ClinicalTrials.gov record NCT05112315. Inclusion in this directory is not an endorsement.